BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8680379)

  • 1. New treatment strategies in cystic fibrosis: rhDNase.
    Shah PL; Hodson ME
    Monaldi Arch Chest Dis; 1996 Apr; 51(2):125-9. PubMed ID: 8680379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
    Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
    Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNase trials in cystic fibrosis.
    Hodson ME; Shah PL
    Eur Respir J; 1995 Oct; 8(10):1786-91. PubMed ID: 8586138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
    Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
    N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
    Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
    Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
    Shak S
    Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis--an overview.
    Hodson ME
    Respiration; 1995; 62 Suppl 1():29-32. PubMed ID: 7792438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical development of rhDNase in the United States].
    Eisenberg J
    Arch Pediatr; 1995 Jul; 2(7):674-8. PubMed ID: 7663659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
    Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
    Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.
    Wilmott RW; Amin RS; Colin AA; DeVault A; Dozor AJ; Eigen H; Johnson C; Lester LA; McCoy K; McKean LP; Moss R; Nash ML; Jue CP; Regelmann W; Stokes DC; Fuchs HJ
    Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1914-7. PubMed ID: 8665055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
    Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
    Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
    Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
    Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis.
    Suri R
    BioDrugs; 2005; 19(3):135-44. PubMed ID: 15984899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
    Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
    Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
    Hodson M
    Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group.
    Fiel SB; Fuchs HJ; Johnson C; Gonda I; Clark AR
    Chest; 1995 Jul; 108(1):153-6. PubMed ID: 7606951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
    Suri R; Metcalfe C; Wallis C; Bush A
    Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of recombinant human DNase in cystic fibrosis patients.
    Aitken ML
    Monaldi Arch Chest Dis; 1993 Dec; 48(6):653-6. PubMed ID: 8124306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.